Press Release Distribution
 

Members Login  |  Register  |  Why Join?   Subscribe to Newsletter Newsletter   RSS Feeds RSS Feeds

Video Releases    |    Pricing & Distribution Plans    |    Today's News    |    News By Category    |    News By Date    |    Business Directory
All Press Releases for November 02, 2012 »
RSS Feeds RSS Feed     Print this news Printer Friendly     Email this news Email It    Create PDF PDF Version   



Bond & Taylor Warns Consumers that Study Links Actos to Bladder Cancer
The law firm Bond & Taylor is warning consumers that a recent study links Actos to bladder cancer. Consumers who have developed bladder cancer after taking Actos are encouraged to call the law firm of Bond & Taylor today. 
x-small text small text medium text large text


    IRVINE, CA, November 02, 2012 /24-7PressRelease/ -- The law firm of Bond & Taylor is warning consumers of a study linking popular type 2 diabetes medication, Actos , to bladder cancer. This newest study, published in the Journal of the National Cancer Institute was contributed by researchers at the Perelman School of Medicine at the University of Pennsylvania. Researchers found that patients taking thiazolidinedione (TZD) drugs such as Actos (Pioglitazone) were two to three times more likely to develop bladder cancer than patients who took sulfonylurea drugs. This is especially disturbing news because TZDs are prescribed to an estimated 20% of diabetes patients today.

This study reinforces government regulators' opinions. In June 2011, the U.S. Food and Drug Administration released a warning to consumers that Actos was under review for safety concerns. The FDA stated that based on a ten year meta study of Actos patients, consumers who took Actos for a year or longer were as much as 40% more likely to suffer from bladder cancer. According to the FDA, an estimated 2.35 million Americans filled a prescription for Actos last year alone, and over 15 million prescriptions are written for this type 2 diabetes drug worldwide.

According to the National Cancer Institute, there are an estimated 70,530 cases of bladder cancer in the U.S. each year and 14,680 deaths. These numbers could rise significantly based upon Actos performance in recent studies. Bond & Taylor is encouraging patients taking Actos to review potential side effects with their doctor. Should a patient develop bladder cancer, the law firm of Bond & Taylor would like to offer a free consultation to discuss eligibility for compensation.

Extensive product liability experience gives Andrew L. Wright the expertise necessary to handle your defective prescription drug case. With over 20 years of experience as a trial lawyer, Andrew L. Wright is used to staring down the prescription drug makers and achieving results for his clients.

The law firm of Bond & Taylor has over 30 years of experience fighting zealously on behalf of injured clients and grieving families who have lost loved ones due to negligence. Bond & Taylor's product liability attorneys are experts at fighting to achieve the justice clients deserve. The attorneys at Bond & Taylor are passionate advocates who treat clients with compassion and respect. Our firm wants to help clients obtain the compensation that they need to find relief. Cases are accepted nationwide; call today for a free consultation. (800) 471-0314 http://www.bondtaylorlaw.com


---
Press release service and press release distribution provided by http://www.24-7pressrelease.com


# # #

Read more Press Releases from Catherine Hess:

Share This Story
Spread this story with Facebook, Twitter, Linkedin, and more.

Bookmark and Share
Contact Information:
Catherine Hess
Bond & Taylor

Irvine, CA
USA
Voice: (949) 988-7100
E-Mail: Email us Here
Website: Visit Our Website
Disclaimer:
If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7PressRelease. We are unable to assist you with any information regarding this release. 24-7PressRelease disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.